SCYNEXIS, Inc. (SCYX)
NASDAQ: SCYX · Real-Time Price · USD
0.9900
-0.0700 (-6.60%)
At close: Sep 17, 2025, 4:00 PM EDT
0.9900
0.00 (0.00%)
Pre-market: Sep 18, 2025, 5:40 AM EDT
SCYNEXIS Revenue
SCYNEXIS had revenue of $1.36M in the quarter ending June 30, 2025, with 85.33% growth. This brings the company's revenue in the last twelve months to $3.26M, down -66.30% year-over-year. In the year 2024, SCYNEXIS had annual revenue of $3.75M, down -97.33%.
Revenue (ttm)
$3.26M
Revenue Growth
-66.30%
P/S Ratio
14.93
Revenue / Employee
$116,321
Employees
28
Market Cap
41.51M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3.75M | -136.40M | -97.33% |
Dec 31, 2023 | 140.14M | 135.05M | 2,652.72% |
Dec 31, 2022 | 5.09M | -8.07M | -61.32% |
Dec 31, 2021 | 13.16M | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
SCYX News
- 13 days ago - SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12) - GlobeNewsWire
- 5 weeks ago - SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study - GlobeNewsWire
- 6 months ago - SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 11 months ago - SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 1 year ago - SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit - GlobeNewsWire
- 1 year ago - SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024 - GlobeNewsWire
- 1 year ago - SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire